Free Trial

Cognition Therapeutics Q3 2023 Earnings Report

Cognition Therapeutics logo
$0.58 -0.03 (-4.33%)
As of 02/21/2025 04:00 PM Eastern

Cognition Therapeutics EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.31
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Cognition Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cognition Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Cognition Therapeutics Earnings Headlines

Cognition announces publication of zervimesine manufacturing process
This Crypto Is Set to Explode in February
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
Cognition Therapeutics price target raised to $2 from $1.50 at B. Riley
Cognition announces Phase 2 ‘SHIMMER’ study to be presented at ILBDC
See More Cognition Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cognition Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cognition Therapeutics and other key companies, straight to your email.

About Cognition Therapeutics

Cognition Therapeutics (NASDAQ:CGTX), a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

View Cognition Therapeutics Profile

More Earnings Resources from MarketBeat